Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis
<p><strong>Introduction</strong></p> Late stage clinical trials in non-alcoholic steatohepatitis (NASH) are currently required by the FDA to use a liver biopsy as a primary endpoint. The well reported limitations with biopsy, such as associated risks and sampling error, coupl...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Frontiers Media
2021
|